ReviewFrontiers in oncology2026
Diabetes and cancer: clinical implications for integrated metabolic-oncologic care.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus and cancer are among the most prevalent non-communicable diseases worldwide and increasingly coexist in clinical practice. Epidemiological evidence indicates that type 2 diabetes is associated with elevated risk of several malignancies, including hepatocellular, pancreatic, colorectal, endometrial, and breast cancers. At the same time, cancer and its treatments may significantly disrupt metabolic homeostasis and complicate glycemic control. Therapies such as glucocorticoids, PI3K inhibitors, and immune checkpoint inhibitors can induce hyperglycemia or precipitate new-onset diabetes. Metabolic dysregulation during cancer therapy has been associated with increased infection risk, treatment complications, and adverse clinical outcomes. This review summarizes the epidemiological evidence linking diabetes and cancer and discusses the clinical implications of their bidirectional interaction. The growing coexistence of both conditions highlights the need for integrated metabolic-oncologic care. Proactive glycemic monitoring, individualized antidiabetic therapy selection, and multidisciplinary management may improve treatment tolerance and long-term outcomes in patients with cancer and diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.